Fluidigm raises $10.7M to enhance stem-cell studies
Fluidigm, maker of chips used in genetic analysis systems, has raised $10.7 million of a targeted $14 million round of debt, warrants, rights and securities, according to a regulatory filing with the Securities and Exchange Commission. The South San Francisco company recently announced that it will be launching a new chip to speed and enhance the study and genotyping of stem cells.
Significantly, Fluidigm’s co-founder is Stephen Quake, the Stanford professor of bioengineering who recently announced… Continue Reading
Fluidigm pulls IPO because of weak market conditions
The initial public offering market is still stuck in neutral. Fluidigm was set to go public, but on Monday it postponed its offering, PEHub reported.
The South San Francisco, Calif.-based provider of systems designed to improve the productivity of laboratories had previously planned to issue 5.3 million shares for a total raise of $79.5 million, according to a regulatory filing. The price range was supposed to be $14 to $16 a share.
The IPO would have been… Continue Reading
Roundup: News sparks market mayhem, gamers hate Spore DRM, DoJ eyes Google antitrust case, and more
With both DEMO and TechCrunch 50 going on, there’s almost too much to report. Here are some of the extra bits:
Old news becomes new problem — A six year old article about a United Airlines bankruptcy filing re-appeared on Google News Monday morning, triggering a massive sell-off of the company’s stock and deftly illustrating the potential dangers of modern (dis)information dissemination.
Spore spawns DRM hatred — The much-anticipated game Spore (see our interview with creator Will Wright) has… Continue Reading
Fluidigm, maker of devices to improve life science research, files for IPO
Fluidigm, a company that makes integrated fluidic circuit systems, which make life science research easier by allowing researches to perform thousands of biochemical measurements, has filed for an initial public offering.
The San Francisco company plans to sell up to $86.25 million in common stock.
Fluidigm’s revenues rose to $7.3 million from $6.4 million. However, it reported growing losses: $25.5 million in 2007, up from a loss of $23.6 million in 2006.
Fluidigm has raised nearly $200… Continue Reading
Life science fluid control company, Fluidigm, raises $17M more
Fluidigm Corporation, a South San Francisco life science company focused on “integrated fluidic circuits” that control fluids precisely, said it has raised $37 million so far in its fifth round of venture capital.
The investors include Wasatch Advisors, and its private equity affiliate, Cross Creek Capital, as well as existing investors. The company had previously raised $20.05 million for the round, and the new cash amounts $17 million. Before the fifth round, the company had raised… Continue Reading